Elkassabany Nabil M, Bhatia Jasmine, Deogaonkar Anupa, Barnett Gene H, Lotto Michelle, Maurtua Marco, Ebrahim Zeyd, Schubert Armin, Ference Sandra, Farag Ehab
Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA, USA.
J Neurosurg Anesthesiol. 2008 Jan;20(1):45-8. doi: 10.1097/ANA.0b013e31815d5f1f.
Blood brain barrier disruption enhances drug delivery in primary central nervous system lymphoma. In this study, we report adverse events that were encountered intraoperatively and in the postoperative period in these patients. A retrospective analysis of 17 patients documenting demographic data, preprocedure medical history, intraoperative, and postoperative anesthetic complications was conducted between January 2002 and December 2004. Seventeen patients underwent 210 treatments under general anesthesia with a mean of 12.4+/-7.2 treatments per patient. Focal seizures occurred in 13% of patients. Generalized motor seizures occurred in 4 treatment sessions in 2 different patients. The incidence of seizures was significantly higher when the internal carotid artery was used for injection, as opposed to the vertebral artery (20.8% and 6.02%, respectively, P=0.0034). Tachycardia associated with ST segment depression occurred 9 times (4.3%) in 3 patients. One patient had significant ST segment elevation (more than 1.5 mm). Transient cerebral vasospasm after methotrexate injection occurred in 9% of patients. Postoperative nausea and vomiting were observed in 11.9% of patients. After emergence, lethargy and obtundation occurred in 7.6% of the cases. The incidence of postoperative headache and reversible motor deficits was 6% and 3.8%, respectively. Our review highlights the problems that were encountered during blood brain barrier disruption under anesthesia and in the postoperative period. Further prospective studies are required for comprehensive evaluation of intraprocedure and postprocedure complications that will allow development of an optimal anesthetic plan and will improve patient outcome by preventing potential complications.
血脑屏障破坏可增强原发性中枢神经系统淋巴瘤的药物递送。在本研究中,我们报告了这些患者术中及术后出现的不良事件。对2002年1月至2004年12月期间的17例患者进行了回顾性分析,记录了人口统计学数据、术前病史、术中及术后麻醉并发症。17例患者在全身麻醉下接受了210次治疗,平均每位患者接受12.4±7.2次治疗。13%的患者出现局灶性癫痫发作。2例不同患者在4个治疗疗程中出现全身性运动性癫痫发作。与使用椎动脉相比,使用颈内动脉注射时癫痫发作的发生率显著更高(分别为20.8%和6.02%,P=0.0034)。3例患者出现与ST段压低相关的心动过速9次(4.3%)。1例患者出现显著的ST段抬高(超过1.5毫米)。9%的患者在注射甲氨蝶呤后出现短暂性脑血管痉挛。11.9%的患者出现术后恶心和呕吐。苏醒后,7.6%的病例出现嗜睡和意识模糊。术后头痛和可逆性运动功能障碍的发生率分别为6%和3.8%。我们的综述强调了麻醉下血脑屏障破坏期间及术后遇到的问题。需要进一步的前瞻性研究来全面评估术中及术后并发症,以制定最佳的麻醉方案,并通过预防潜在并发症来改善患者预后。